Publication | Closed Access

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

Phase Ii Open-labelUrologyPancreatic CancerGastrointestinal OncologyMedicineClinical TrialsFirst-line Gemcitabine TherapyPharmacotherapyMetastatic Pancreatic CancerCancer TreatmentOncologyRadiation OncologyMolecular OncologyHealth Sciences